Itraconazole: A Reappraisal of its Pharmacological Properties and Therapeutic Use in the Management of Superficial Fungal Infections

Drugs

Volumn 51, Issue 4, 1996, Pages 585-620

  Haria, Malini ^a   Bryson, Harriet M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA; FUNGI; TINEA;

ANTACID AGENT; ANTIDIABETIC AGENT; ASTEMIZOLE; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; FELODIPINE; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; RANITIDINE; RIFAMPICIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; WARFARIN;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASTHMA; CONJUNCTIVITIS; COUGHING; DEPRESSION; DERMATOMYCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG ERUPTION; DRUG MECHANISM; DYSPEPSIA; ECZEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LASSITUDE; MALAISE; MIGRAINE; MYALGIA; MYCOSIS; NAUSEA; ONCHOCERCIASIS; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PRURITUS; RESPIRATORY TRACT INFECTION; REVIEW; THORAX PAIN; TINEA VERSICOLOR; VAGINA CANDIDIASIS; VERTIGO; VOMITING;

ABSORPTION; ANTIFUNGAL AGENTS; DOSAGE FORMS; DRUG INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; KIDNEY DISEASES; LIVER DISEASES; MYCOSES; TISSUE DISTRIBUTION;

EID: 0029932717     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00006     Document Type: Article

References (245)

1. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
2. Zuckerman JM, Tunkel AR. Itraconazole: a new triazole antifungal agent. Infect Control Hosp Epidemiol 1994 Jun; 15: 397-410
3. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989 Mar; 37: 310-44
4. Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992; 30: 1-10
5. Odds FC. Antifungal susceptibility testing of Candida spp. by relative growth measurements at single concentrations of antifungal agents. Antimicrob Agents Chemother 1992; 36: 1727-37
6. Rex JH, Pfaller MA, Rinaldi MG, et al. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6: 367-81
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard. Document M27-P, 1992.
8. Pfaller MA, Messer SA, Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J Clin Microbiol 1995 May; 33: 1094-7
9. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995 Feb; 39: 314-9
10. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995; 39: 2051-60
11. Matsumoto T, Ajello L, Matsuda T, et al. Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol 1994; 32 Suppl. 1: 329-49
12. Shadomy S, Espinel-Ingroff A, Gebhart RJ, et al. In vitro studies with SF 86-327, a new orally active allylamine derivative. J Med Vet Mycol 1985; 23: 125-32
13. Korting HC, Ollert M, Abeck D, et al. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-8
14. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994; 32 (4): 267-74
15. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987; 9 Suppl. 1: S15-32
16. Van Cutsem J, Van Gerven F, Janssen PAJ. The in vitro and in vivo antifungal activity of itraconazole. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. S.A: JR Prous Science Publishers, 1987: 177-92
17. Jansen TM, Van de Ven M-AA, Borgers MJ, et al. Fungal morphology after treatment with itraconazole as a single oral dose in experimental vaginal candidosis in rats. Am J Obstet Gynecol 1991 Nov; 165(Pt 1): 1552-7
18. Borgers M, Xhonneux B, Vancutsem J. Oral itraconazole versus topical bifonazole treatment in experimental dermatophytosis. Mycoses 1993 Mar-Apr; 36: 105-15
19. DeMuri GP, Hostetter MK. Resistance to antifungal agents. Pediatr Clin North Am 1995 Jun; 42: 665-85
20. Johnson EM, Warnock DW. Azole drug resistance in yeasts. J Antimicrob Chemother 1995; 36: 751-5
21. Vanden Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994; 32 Suppl. 1: 189-202
22. Denning DW. Can we prevent azole resistance in fungi? Lancet 1995 Aug 19; 346: 454-5
23. Arias A, Arévalo MP, Andreu A, et al. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses 1994; 37: 285-9
24. White DJ, Johnson EM, Warnock DW. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993 Apr; 69: 112-4
25. Fong IW, Bannatyne RM, Wong P. Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis. Genitourin Med 1993 Feb; 69: 44-6
26. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994 Jan 27; 330: 263-72
27. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990; 10(2): 146-53
28. Brummer E, Bhagavathula PR, Hanson LH, et al. Synergy of itraconazole with macrophages in killing Blastomyces dermatitidis. Antimicrob Agents Chemother 1992 Nov; 36: 2487-92
29. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995 Mar; 32: 429-35
30. Van Cutsem J, Van Gervan F. The fungicidal activity of itraconazole and terbinafine: in vitro against dermatophytes, in vivo in trichophytosis in guinea-pig [poster]. World Congress of Dermatology, New York, New York, USA, 1992 June 12-18
31. Borgers M. Changes in fungal ultrastructure after itraconazole treatment. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. S.A: JR Prous Science Publishers, 1987
32. Borgers M, Van de Van M. Degenerative changes in fungi after itraconazole treatment. Rev Infect Dis 1987; 9 Suppl. 1: 33-42
33. Odds FC, Cockayne A, Hayward J, et al. Effects of imidazole-and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol 1985; 131: 2581-9
34. Faergemann J, Borgers M. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Derm Venereol 1990; 70 (2): 172-6
35. Del Palacio-Hernanz A, Frias-Iniesta J, Gonzalez-Valle O, et al. Itraconazole therapy in pityriasis versicolor. Br J Dermatol 1986; 115: 217-25
36. Galimberti RL, Villalba I, Galarza S, et al. Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia fur-fur produced during treatment. Rev Infect Dis 1987; 9 Suppl. 1: 134-8
37. Vanden Bossche H, Marichal P, Gorrens J, et al. Interaction of azole derivatives with cytochrome P-450 isoenzymes in yeast, fungi, plants and mammalian cells. Pestic Sci 1987; 21: 289-306
38. Phillips F, Graybill JR, Fetchick R, et al. Adrenal response to corticotrophin during therapy with itraconazole. Antimicrob Agents Chemother 1987; 31: 647-9
39. De Coster R, Beerens D, Haelterman C, et al. Effects of itraconazole on the pituitary-testicular-adrenal axis: an overview of preclinical and clinical studies. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. S.A: JR Prous Science Publishers, 1987: 251-61
40. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 1: 67-87
41. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993 Apr; 37: 778-84
42. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-3
43. Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988 Oct; 32: 1595-7
44. Smith D, Van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1492 Jul; 44: 618-9
45. Bradford CR, Prentice AG, Warnock DW, et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 1991 Oct; 28: 555-60
46. Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of a new cyclodextrin solution formulation of itraconazole (ITR) in patients undergoing remission induction chemotherapy for acute myeloid leukemia [abstract no. 744]. 32nd Interscience Conference on Antimicrobial Agents in Chemotherapy, California, USA, 1992 Oct 11-14; 234.
47. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet 1991 Jun 29; 337: 1577-80
48. Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by me abolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993 Oct; 37: 2224-7
49. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994 Jul; 38: 1561-6
50. Badcock NR, Davies A. Assay of itraconazole in nail clippings by reversed phase, high performance liquid chromatography. Ann Clin Biochem 1990 Sep; 27: 506-8
51. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988 Sep; 32: 1310-3
52. Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993 Jun; 7: 317-21
53. Schäfer-Korting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 1993 Oct; 25: 329-41
54. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8
55. Gorlero F, Larosa E, Cauwenbergh G, et al. Itraconazole plasma and vaginal mucosal levels in patients with chronic vaginal candidosis treated with itraconazole 200mg once daily for 3 consecutive days. Drug Invest 1993 Jul; 6: 22-4
56. De Doncker P, Pierard G, Arrese J, et al. Itraconazole nail kinetics: the biphasic sequence of diffusion and incorporation into the nail is the key to nail penetration [abstract no. P-230]. Annual Meeting of the American Academy of Dermatology, New Orleans, Louisiana, USA, 1995 Feb 5-9.
57. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992 May; 26: 731-5
58. Schafer-Korting M, Korting HC, Lukacs A, et al. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol 1990 Feb; 22: 211-5
59. Cauwenbergh G. Skin kinetics of azole antifungal drugs. Curr Top Med Mycol 1992; 4: 88-136
60. Decroix J. Tinea pedis (mocassin-type) treated with itraconazole. Int J Dermatol 1995 Feb; 34: 122-4
61. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991 Sep; 16: 374-6
62. Janssen Pharmaceutica. Itraconazole prescribing information, New Jersey, USA, 1995.
63. Arredondo G, Martinez-Jorda R, Calvo R, et al. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994 Jul; 32: 361-4
64. Puttick MPE, Phillips P. Itraconazole: precautions regarding drug interactions and bioavailability. Can J Infect Dis 1994 Jul-Aug; 5: 179-83
65. Persat F, Marzullo C, Guyotat D, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992 Apr-May; 28A: 838-41
66. Caillot D, Casasnovas RO, Solary E, et al. Oral solution of itraconazole (ITR): study of tolerance and plasma concentrations in neutropenic patients [abstract no. 743]. 32nd Interscience Conference on Antimicrobial Agents in Chemotherapy. California, USA, 1992 Oct 11-14; 234.
67. Arredondo G, Calvo R, Marcos F, et al. Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther 1995 Aug; 33: 449-52
68. Clayton YM. Clinical and mycological aspects of onychomycosis. JAMA South East Asia 1993: 9 Suppl. 4: 7-10
69. Zaias N. Clinical manifestations of onychomycosis. Clin Exp Dermatol 1992; 17 Suppl. 1: 6-7
70. Adams JD. My approach to fungal nail disorders. Curr Ther 1990; 31: 108-13
71. Hay RJ. Onychomycosis. Agents of choice. Dermatol Clin 1993 Jan; 11: 161-9
72. Goodman GJ. Contemporary treatment of onychomycosis. Persistence is the 'name of the game'. Curr Ther 1986; 28: 43-55
73. Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49: 103-20
74. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-66
75. Rongioletti F, Robert E, Tripodi S, et al. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992 Jan; 2: 145-6
76. Walsøe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Open and double-blind studies. Acta Derm Venereol 1990; 70(2): 137-40
77. Dinotta F, Puccia N, Mangano R, et al. Itraconazole in the treatment of onychomy coses [in Italian]. Micol Dermatol 1991; 5: 30-3
78. Vidal G, Rodriguez De Kopp N. Tratamiento de las onicodistrofias micóticas con dos esquemas posológicos de itraconazol. Rev Arg Micologia 1993; 16: 25-32
79. Cabral F, Couto J, Velho R. Itraconazole in the treatment of onychomycoses [in Portuguese]. Trab Soc Port Derm Ven 1988; XLVI: 157-60
80. Chang P, Lima HL. Tratamiento de onicomicosis con itraconazol. Evaluación abierta en 18 pacientes. Dermatologia Rev Mex 1994; 38: 342-6
81. Kim J-A, Ahn K-J, Kim J-M, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56: 1066-75
82. Arenas R, Fernández G, Domínguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic Agent. Int J Dermatol 1991 Aug; 30: 586-9
83. Korting HC, Schäfer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993 Oct; 37: 2064-8
84. Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother 1992 Feb; 29: 195-205
85. Arenas R, Domínguez-Cherit J, Fernández LMA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis [abstract]. Int J Dermatol 1995 Feb; 34: 138-43
86. Bräutigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection [published erratum appears in BMJ 1995; 311: 1350]. BMJ 1995; 311: 919-22
87. Zaias N, Drachman D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol 1983; 9: 912-9
88. Haneke E, Delescluse J, Plinck EPB. The use of itraconazole in onychomycosis: a review. Eur J Dermatol. In press
89. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993 Jul; 29: S45-50
90. Scher RK, Barnett JM. Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole. J Am Acad Dermatol 1990 Oct; 23: 749-50
91. André J, De Doncker P, Laporte M, et al. Onychomycosis caused by Microsporum canis: treatment with itraconazole. J Am Acad Dermatol 1995 Jun; 32: 1052-3
92. De Doncker P, Scher R, Decroix J, et al. Efficacy of itraconazole pulse therapy for the treatment of nondermatophyte onychomycosis of the toenail [abstract no. P-230]. Annual Meeting of the American Academy of Dermatology, New Orleans, Louisiana, USA, 1995 Feb 5-9.
93. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial mycoses. Drugs 1992; 43: 259-84
94. Arikian SR, Einarson TR, Kobelt-Nguyen G. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994 Apr; 130 Suppl. 43: 35-44
95. Stary A, Storch M, Hörting-Müller I, et al. Systemic treatment of onychomycosis with itraconazole: clinical and mycological results [abstract no. B039]. 3rd Congress of the European Academy of Dermatology and Venereology, Copenhagen, Denmark, 1993 Sept 26-30; 348.
96. Urbanowski S, Gwiezdzinski Z, Nierebinska E, et al. Itraconazole in the 3 month therapy of onychomycosis: is a subsequent pulse necessary? A double-blind randomized study [abstract no. 810]. Dermatology 2000 Vienna, Vienna, Austria, 1993 May 18-21; 294.
97. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy for onychomycosis. Arch Dermatol 1996; 132: 34-41
98. André J, De Doncker P, Ginter G, et al. Intermittent pulse therapy with itraconazole in onychomycosis: an update [abstract no. P239]. J Eur Acad Dermatol Venerol 1995 Oct; 5 Suppl. 1: S173-4
99. André J, Havu V. European experience with itraconazole pulse therapy in the treatment of toenail onychomycosis. Proceedings of the 2nd International Symposium on Onychomycosis. Florence, Italy, 1995 Sept 28-29.
100. Rezabek GH, Friedman AD. Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs 1992; 43: 674-82
101. Degreef HJ, De Doncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994 Sep; 31 (3 Pt 2): S25-30
102. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992; 17 Suppl. 1: 37-40
103. Panagiotidou D, Kousidou T, Chaidemenos G, et al. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Int Med Res 1992 Sep; 20: 392-400
104. Lachapelle JM, De Doncker P, Tennstedt D, et al. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 1992; 184: 45-50
105. Alcántara R, Garibay JM. Itraconazol en dermatomicosis: evaluación multicentrica. Invest Med Int 1988; 14: 281-6
106. Degreef H, Mariën K, De Veylder H, et al. Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Rev Infect Dis 1987; 9 Suppl. 1: 104-8
107. Saúl A, Bonifaz A, Arias I. Itraconazole in the treatment of superficial mycoses: an open trial of 40 cases. Rev Infect Dis 1987; 9 Suppl. 1: 100-8
108. De Doncker P, Cauwenbergh G. Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. Br J Clin Pract Symp Suppl. 1990 Sep; 71: 118-22
109. Difonzo EM, Panconesi E, Cilli P. Itraconazole in dermatophyte infections: clinical experience in Italy. Br J Clin Pract 1990 Sep; 44 Suppl. 71: 114-7
110. Katsambas A, Antoniou CH, Frangouli E, et al. Itraconazole in the treatment of tinea corporis and tinea cruris. Clin Exp Dermatol 1993 Jul; 18: 322-5
111. Noppakun N, Phuphaibool K. Treatment of dermatophytosis with new systemic antifungal agent, itraconazole. J Med Assoc Thai 1992 Feb; 75: 99-103
112. Alchorne MMA, de Almeida FA, Castro RM, et al. Itraconazole - multicentric study in dermatophytosis [in Portuguese]. Rev Bras Med 1991 Apr; 48: 197-200
113. Zaitz C, Ruiz LRB, Drullis EMA, et al. Clinical trial with itraconazole in the treatment of tinea-cruris, tinea-corporis and tinea-pedis-interdigital [in Portuguese]. Rev Inst Med Trop Sao Paulo 1990 Jul-Aug; 32: 299-303
114. Fioroni A, Cilli P, Altomare G, et al. Therapy of dermatomycosis with a new oral antimycotic drug. Itraconazole [in Italian]. G Ital Dermatol Venereol 1991; 126: 27-32
115. Kagawa S. A clinical study of the oral antimycotic agent itraconazole in cases of superficial dermatomycosis [in Japanese]. Kiso to Rinsho 1991; 25: 409-21
116. Pariser DM, Pariser RJ, Ruoff G, et al. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. J Am Acad Dermatol 1994 Aug; 31 (Pt 1): 232-4
117. Roseeuw D, Willemsen M, Kint R, et al. Itraconazole in the treatment of superficial mycoses - a double-blind study vs placebo. Clin Exp Dermatol 1990 Mar; 15: 101-4
118. Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989 Jul-Aug; 28: 410-2
119. del Palacio A, Van Cutsem J, López S, et al. A comparative double-blind study of itraconazole and griseofulvin in tinea corporis and tinea cruris [in Spanish]. Rev Iberoam Micol 1993; 10: 51-8
120. Finz A, Cilli P. Italian mullicentre trial comparing itraconazole with griseofulvin in the treatment of dermatomycoses. Preliminary results. J Eur Acad Dermatol Venerol 1992 Suppl. 1: S15-8
121. Notowicz A, Koster M. Itraconazole versus griseofulvin. A double-blind comparison in patients with tinea corporis and tinea cruris. J Dermatol Treat 1992 Mar; 3: 23-5
122. Van Hecke E, Van Cutsem J. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988; 31: 641-9
123. Wishart JM. A double blind study of itraconazole vs griseofulvin in patients with tinea pedis and tinea manus. N Z Med J 1994 Apr 13; 107: 126-8
124. Difonzo EM, Papini M, Cilli P, et al. A double-blind comparison of itraconazole and fluconazole in tinea pedis and tinea manuum. J Eur Acad Dermatol Venerol 1995; 4: 148-52
125. Lospalluti M, Barile F, Pantaleo AK, et al. A comparison of 50 mg and 100 mg fluconazole vs 100 mg itraconazole for epidermal mycoses [in Italian]. Clin Ter 1994 Feb; 144: 129-38
126. Budimulja U, Kuswadji K, Bramono S, et al. A double-blind, rat domized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994 Apr; 130 Suppl. 43: 29-31
127. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994 Apr; 130 Suppl. 43: 22-5
128. Hay RJ, McGregor JM, Wuite J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995 Apr; 132: 604-8
129. Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189 (4): 378-81
130. Rakesi T. Itraconazole in treatment of dermatomycoses. Dermatology 1992; 185 (3): 225
131. Gupta A, De Doncker P, Heremans A, et al. Itraconazole in tinea pedis: a dose of 400 mg/day given for 1 week is more effective than 100 or 200 mg/day given for 2-4 weeks [abstract no. P238]. J Eur Acad Dermatol Venerol 1995 Oct; 5 Suppl. 1: S173
132. Papini M, Calandra P. Itraconazole in the prophylaxis and treatment of superficial fungal infections [in Italian]. Micol Dermatol 1989; 3: 50-4
133. Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 1990 Sep; 23: 559-60
134. Dhondt A, Cauwenbergh G, De Doncker P. Short oral therapy in difficult-to-treat tinea infections. J Eur Acad Dermatol Venerol 1992 Suppl. 1: S11-4
135. Retanda G, Chiarolini F, Ena P. et al. Treatment of tinea capitis with a new triazolic antimycotic drug: itraconazol [in Italian]. G Ital Dermatol Venereol 1991; 126: 15-7
136. Lopez-Gomez S, Del-Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children [see comments]. Int J Dermatol 1994 Oct; 33: 743-7
137. Hay RJ, Roberts SOB, Mackenzie DWR. Mycology. In: Champion RH, Burton JL, Ebling FJG, editors. Texbook of dermatology. 5th ed. vol. 2. Oxford: Blackwell Scientific Publications, 1992: 1127-216
138. Biggio P, Aste N, Pau M. Treatment of pityriasis versicolor with itraconazole (R51-211): preliminary results [in Italian]. Dermatol Clin (Rome) 1986; 3: 251-5
139. Estrada RA. Itraconazole in pityriasis versicolor. Rev Infect Dis 1987; 9 Suppl. 1: 128-30
140. Cuce LC, Belda Jr W, Ribeiro EB de O. Itraconazole in the treatment of Pityriasis versicolor: a comparison between 5 and 7 days of treatment [in Portuguese]. Rev Inst Med Trop Sao Paulo 1990 May-Jun; 32: 181-4
141. Difonzo EM, Cilli P, Panconesi E. Itraconazole in the prophylactic treatment of recurrent pityriasis versicolor: results of a multicentric Italian study [in Italian]. Semin Dermatol 1993: 3-16
142. Morales-Doria M. Pityriasis versicolor: efficacy of two five-day regimens of itraconazole. Rev Infect Dis 1987; 9 Suppl. 1: 131-3
143. Del Palacio-Hernanz A, Delgado Vicente S, Menéndez Ramos F, et al. Randomised comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9 Suppl. 1: 121-7
144. Maddin S. A clinical evaluation of itraconazole versus clotrimazole in patients with pityriasis versicolor. Can J Dermatol. In press
145. Köse O. Fluconazole versus itraconazole in the treatment of tinea versicolor. Int J Dermatol 1995 Jul; 34: 498-9
146. Rein MF. Vulvovaginitis and cervicitis. In: Mandell GL, Douglas Jr RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 953-65
147. Anonymous. Drugs acting on the skin. In: Prasad AB, editor. British National Formulary 27th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1994: 407-51
148. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152: 924-35
149. Wesel S. Itraconazole: a single-day oral treatment for acute vulvovaginal candidosis. Br J Clin Pract 1990 Sep; 44 Suppl. 71: 77-80
150. Baraggino E, Orsetti G, Ribaric G, et al. Preliminary clinical study of the use of itraconazole in the treatment of vulvovaginal candidiasis [in Italian]. Minerva Ginecol 1991 Dec; 43: 601-4
151. Roongpisuthipong A, Bhiraleus P, Sukroongreung S, et al. Itraconazole in the treatment of aeute vaginal candidosis. J Med Assoc Thai 1992 Jan; 15: 30-4
152. Romanowski B, Austin TW, Steben M, et al. Oral itraconazole versus vaginal clotrimazole in the treatment of patients with acute vulvovaginal candidiasis [abstract]. Sex Transm Dis 1994 Mar-Apr; 21 Suppl: 177
153. Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother 1993 Jan; 37: 89-92
154. Tobin JM, Loo P, Granger SE. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin Med 1992 Feb; 68: 36-8
155. Timonen H, Hartikainen-Vahtera P, Kivijärvi A, et al. A double-blind comparison of the effectiveness of itraconazole oral capsules with econazole vaginal capsules in the treatment of vaginal candidosis. Drug Invest 1992; 4 (6): 515-20
156. Rees T, Phillips R. Multicenter comparison of one-day oral therapy with fluconazole or itraconazole in vaginal candidiasis. Int J Gynecol Obstet 1992; 37 Suppl: 33-8
157. Woolley PD, Higgins SP. Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. Br J Clin Pract 1995 Mar-Apr; 49: 65-6
158. Fong IW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med 1992 Dec; 68: 374-7
159. Creatsas GC, Charalambidis VM, Zagotzidou EH, et al. Chronic or recurrent vaginal candidosis: short-term treatment and prophylaxis with itraconazole. Clin Ther 1993 Jul-Aug; 15: 662-71
160. Goh CL. Cutaneous cryptococcosis successfully treated with itraconazole. Cutis 1993 May; 51: 377-80
161. Sato T, Koseki S, Takahashi S, et al. Case report - localized cutaneous cryptococcosis successfully treated with itraconazole - review of medication in 18 cases reported in Japan. Mycoses 1990 Sep-Oct; 33: 455-63
162. Pierard GE, Rurangirwa A, Estrada JA, et al. Cutaneous protothecosis treated with itraconazole [in French]. Ann Soc Belg Med Trop 1990 Jun; 70: 105-12
163. Smith CH, Barker JNWN, Hay RJ. A case of chromoblastomycosis responding to treatment with itraconazole. Br J Dermatol 1993 Apr; 128: 436-9
164. Kullavanijaya P, Rojanavanich V. Successful treatment of chromoblastomycosis due to Fonsecaea pedrosoi by the combination of itraconazole and cryotherapy. Int J Dermatol 1995; 34: 804-7
165. Yu R-Y. Successful treatment of chromoblastomycosis with itraconazole. Mycoses 1995; 38: 79-83
166. Duffill MB, Coley KE. Cutaneous phaeohyphomycosis due to Alternaria alternata responding to itraconazole. Clin Exp Dermatol 1993 Mar; 18: 156-8
167. Lanigan SW. Cutaneous Alternaria infection treated with itraconazole. Br J Dermatol 1992 Jul; 127: 39-40
168. Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992 May-Jun; 35: 153-6
169. Tucker RM, Denning DW, Arathoon EG, et al. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990 Sep; 23: 593-601
170. Chuan M-T, Wu M-C. Subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei: successful treatment with itraconazole. Int J Dermatol 1995 Aug; 34: 563-6
171. Lee MW, Kim JC, Choi JS, et al. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol 1995 May; 32 (Pt 2): 897-900
172. Resnik BI, Burdick AE. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1995; 33: 917-9
173. Dogra J, Aneja N, Lal BB, et al. Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51-211 Janssen). Int J Dermatol 1990 Nov; 29: 661-2
174. Akuffo H, Dietz M, Teklemariam S, et al. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1990 Jul-Aug; 84: 532-4
175. Al-Fouzan AS, Al Saleh QA, Najem NM, et al. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol 1991 Jul; 30: 519-21
176. Albanese G, Giorgetti P, Santagostino L, et al. Cutaneous leishmaniasis. Treatment with itraconazole. Arch Dermatol 1989 Nov; 125: 1540-2
177. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341-8
178. Davis R, Balfour JA. Terbinafine: a pharmacoeconomic evaluation of its use in superficial fungal infections. PharmacoEconomics 1995 Sep; 8: 253-69
179. Kobelt-Nguyen G, van AD. Mycosis of finger and toe nails: pharmacoeconomic analysis of oral treatment in Germany [in German]. Z Allgemeinmed 1994 Sep 5; 70: 683-5
180. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl. 43: 32-4
181. Bergman W, Rutten FFH. Cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine in the oral treatment of onychomycosis of the toenail [in Dutch]. Ned Tijdschr Geneeskd 1994; 138: 2346-50
182. Dubois D. Cost-effectiveness of antifungal therapy. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy, 1995 Sep 28-29.
183. Cauwenberg G, Legendre R, Blatchford N. Itraconazole, a novel oral antifungal: its efficacy and safety profile. 8th Regional Conference of Dermatology; Bali; June 16-20.
184. Hay RJ. Safety of antifungal pulse therapy. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, Italy, 1995 Sept 28-29
185. Inman W, Kubota K, Pearce G, et al. PEM Report Number 7. Itraconazole. Pharmacoepidemiol Drug Saf 1993 Jul-Oct; 2: 423-43
186. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management. Drug Saf 1992 Sep-Oct; 7: 323-63
187. Tucker RM, Haq Y, Denning DW, et al. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990 Oct; 26: 561-6
188. De Beule K, Lubin G, Cauwenbergh G. Safety aspects of itraconazole therapy in vaginal candidosis, dermatomycosis, and onychomycosis. A review. Curr Ther Res 1991; 49: 814-22
189. Restrepo A, Robledo J, Gómez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413-7
190. Collazos J, Mayo J. Martínez E, et al. Unusual liver toxicity due to the new antifungal agents fluconazole and itraconazole. Int Hepatol Commun 1995 Feb; 3: 112-5
191. Gallardo-Quesada S, Luelmo-Aguilar J, Guanyabens-Calvet C. Hepatotoxicity associated with itraconazole [letter]. Int J Dermatol 1995 Aug; 34: 589
192. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, et al. Liver damage during administration of itraconazole (Trisporal) [in Dutch]. Ned Tijdschr Geneeskd 1993 Jan 2; 137: 38-41
193. Hann SK, Kim JB, Im S, et al. Itraconazole-induced acute hepatitis [letter]. Br J Dermatol 1993; 129: 500-1
194. Sharkey PK, Rinaldi MG, Lerner CJ, et al. High dose itraconazole in the treatment of severe mycoses [abstract no. 575]. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; Los Angeles, USA; 1988 Oct 23-26
195. Nelson MR, Smith D, Erskine D, et al. Ventricular fibrillation secondary to itraconazole induced hypokalaemia. J Infect 1993 May; 26: 348
196. Costa I, Castanet J, Lacour JP, et al. Vertigo and hypokalaemia: two rare adverse effects of itraconazole [in French]. Therapie 1994 Mar-Apr; 49: 149
197. Rosen T. Debilitating edema associated with itraconazole therapy. Arch Dermatol 1994 Feb; 130: 260-1
198. Heymann WR, Manders SM. Itraconazole-induced acute generalized exanthemic pustulosis. J Am Acad Dermatol 1995 Jul; 33: 130-1
199. Cleveland KO, Campbell JW. Hallucinations associated with itraconazole therapy. Clin Infect Dis 1995 Aug; 21: 456
200. Janssen Pharmaceutical Limited. Itraconazole prescribing information. United Kingdom.
201. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995 Jul; 33: 134-5
202. Kwan JTC, Foxall PJD, Davidson DGC, et al. An interaction of cyclosporin and itraconazole. Lancet 1987; 2: 282
203. Trent D, Brett W, Jähnchen E, et al. Time course of cyclosporine/itraconazole interaction. Lancet 1987; 2: 1335-6
204. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients Ann Intern Med 1990 Aug 15; 113: 327-9
205. McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporin-A pharmacokinetics studied using a population approach [abstract]. Ther Drug Monit 1995 Aug; 17: 400
206. Nováková I, Donnelly P, DeWitte T, et al. Itraconazole and cyclosporin nephrotoxicity. Lancet 1987; 2: 920-1
207. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992 Nov; 15: 886-7
208. Rex J. Itraconazole-digoxin interaction. Ann Intern Med 1992 Mar 15; 116:525
209. Alderman CP, Jersmann HPA. Digoxin-itraconazole interaction [letter]. Med J Aust 1993 Dec 6-20; 159: 838-9
210. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993 Mar; 16: 400-3
211. McClean KL, Sheehan GJ. Interaction between itraconazole and digoxin [letter]. Clin Infect Dis 1994 Feb; 18: 259-60
212. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Engl J Med 1995 Sep 7; 333: 664-5
213. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 May; 55: 481-5
214. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 Dec; 56: 501-7
215. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995; 40: 270-2
216. Pillans PI, Sparrow MJ. Pregnancy associated with a combined oral contraceptive and itraconazole. N Z Med J 1993 Oct 13; 106-436
217. Pohjo a-Sintonen S, Viitasalo M, Toivonen L. Itraconazole prevenls terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45 (2): 191-3
218. Kivistö KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994 Jul; 27: 1-5
219. Crane JK, Shin H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993 Oct; 95: 445-6
220. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repclarization pharmacodynamics. J Clin Pharmacol 1993 Dec 33: 1201-6
221. Anon. Interactions with astemizole. Int Pharm J 1993 Jan-Feb; 7: 10
222. Murphy JA, Ross LM, Gibson BES. Vincristine toxicity in five children with acute lymphoblastic leukaemia [letter]. Lancet 1995 Aug 12; 346: 443
223. Yeh J, Soo S-C, Summerton C, et al. Potentiation of action of warfarin by itraconazole. BMJ 1990 Sep 29; 301: 669
224. 2 blockers [abstract]. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, USA, 1994: 39
225. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992 Jan; 14: 165-74
226. Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine and itraconazole, Drug Saf 1993 Oct; 9: 309-11
227. Moreno F, Hardin TC, Rinaldi MG, et al. Itraconazole-didanosine excipient interaction [letter]. JAMA 1993 Mar 24-31; 269: 1508
228. Smith JA, Hardin TC, Patterson TF, et al. Rifabutin (RIF) decreases itraconazole (ITRA) plasma levels in patients with HIV-infection [abstract no. 126]. 2nd National Conference on Human Retroviruses and Related Infections, Washington DC, USA, 1995 Jan 29-Feb 2; 77.
229. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994 Feb; 18: 266
230. Blomley M, Teare EL, de Belder A, et al. Itraconazole and antituberculosis drugs [letter]. Lancet 1990 Nov 17; 336: 1255
231. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90
232. Janssen Pharmaceutica. Ketoconazole prescribing information. New Jersey, USA, 1995.
233. Janssen Pharmaceutica. Itraconazole International Product Information, Belgium, 1995.
234. Piérard GE, Arrese-Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993 Jul; 29: S41-5
235. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994 Sep; 31 (3 Pt 2): S78-81
236. Adam BA. Nail disease: onychomycosis and paronychia. Med Dig 1994 Aug; 20: 5-11
237. Cohen JL, Scher RK, Pappert AS. The nail and fungus infections. In: Elewski BE, editor. Topics in clinical dermatology. Cutaneous fungal infections. 1st ed. ; Igaku-Shoin Medical Publishers Inc. New York, 1992: 106-23
238. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ 1967; 3: 464-8
239. Kaden R. Klinische und Mykolugische Nachuntersuchungen Griseofulvin Behandelter Onychomykosen [in German]. Mycopathol Mycol Appl 1965; 25: 351-60
240. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243-8
241. Hay RJ. Treatment of dermatomycoses and onychomycoses - state of the art. Clin Exp Dermatol 1992; 17 Suppl. 1: 2-5
242. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993 Jul; 29: S50-4
243. Denning DW, Evans EGV, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ 1995; 311: 1277-81
244. Elewski BE. Onychomycosis. Fitzpatrick's J Clin Dermatol 1994 Nov/Dec: 48-54
245. Delescluse J. Itraconazole in tinea versicolor: a review. J Am Acad Dermatol 1990 Sep; 23: 551-4